Sign In
Get Clay Free →

Suggestions

    Kanad Das

    Investment Director, Boehringer Ingelheim Venture Fund

    Professional Background

    Kanad Das is an accomplished professional in the field of life sciences, with a particular focus on drug discovery and development. With a career spanning over a decade, Kanad has effectively navigated various roles that intersect the areas of science, business, and venture funding. As the current Investment Director at Boehringer Ingelheim Venture Fund, he plays a pivotal role in identifying and investing in innovative biotechnology companies that are set to transform the healthcare landscape. Kanad's extensive experience allows him to build strategic partnerships and guide emerging companies toward success in a competitive industry.

    Before his tenure at Boehringer Ingelheim, Kanad served on the Board of Directors at Actym Therapeutics, Inc. and OncoMyx Therapeutics, where his insights guided organizational strategy and contributed to advancements in cancer therapies. His leadership at these companies reflects his commitment to driving innovation and his deep understanding of the therapeutic development process.

    Kanad's career also includes significant expertise in business development. As a former Director of Business Development at Merck, he was instrumental in shaping collaborations that leverage new technologies in biopharmaceutical development. His role required a keen understanding of the scientific landscape and the ability to align business objectives with cutting-edge research.

    Education and Achievements

    Kanad Das possesses a robust academic foundation, having earned his Ph.D. in Chemistry from the University of Massachusetts, Amherst. His doctoral research equipped him with analytical and problem-solving skills that are crucial in both scientific research and business management. In addition to his advanced degree, Kanad earned a Bachelor of Science in Chemistry from the prestigious University of California, Berkeley, where he developed a strong focus on organic chemistry and its applications in drug development.

    At the start of his academic journey, Kanad laid a solid groundwork at John Jay High School, where he showed early promise in science and mathematics, paving the way for his future pursuits in chemistry and life sciences.

    Throughout his career, Kanad has contributed significantly to the fields of chemistry and pharmaceutical sciences, exemplified by his roles at prominent organizations such as Stanford University's SPARK Program. As Associate Director of SPARK Partnering and Alliance Management, Kanad managed collaborations between academic researchers and industry partners, facilitating the transfer of innovative ideas from the lab to real-world applications. His advisory role at Dermira, Inc. further highlights his ability to influence key decisions that drive therapeutic advancements.

    Kanad also gained valuable experience as a Senior Scientist at KAI Pharmaceuticals and as a Post-Doctoral researcher at Genentech. His work in these positions involved cutting-edge research that has helped shape the current understanding of small molecule therapeutics and their clinical applications.

    Kanad's journey reveals a professional dedicated to advancing drug discovery while fostering growth in the biotech ecosystem. His blend of scientific expertise and strategic business acumen makes him a leading figure in venture funding and biopharmaceutical innovation.

    Achievements

    • Served as Investment Director at Boehringer Ingelheim Venture Fund, driving investments in transformative biotech companies.
    • Actively participated on the Board of Directors for Actym Therapeutics and OncoMyx Therapeutics, guiding strategic direction in cancer research and treatment.
    • Directed business development initiatives at Merck, successfully facilitating collaborations and partnerships that leverage innovative technologies.
    • Managed SPARK Program at Stanford University, a pioneering initiative that enhances university-industry collaborations around life sciences innovations.
    • Contributed to therapeutic advancements as Senior Scientist at KAI Pharmaceuticals and Post-Doc at Genentech, focusing on small molecule therapeutics and innovative drug strategies.

    Related Questions

    How did Kanad Das develop such a robust academic background in chemistry leading to a successful career in pharmaceuticals?
    In what ways has Kanad Das's role as Investment Director at Boehringer Ingelheim Venture Fund shaped the biotech investment landscape?
    What experiences from his time at Merck have influenced Kanad Das's approach to business development in the life sciences sector?
    How has Kanad Das leveraged his experience in venture funding to support emerging biotech companies?
    What insights can Kanad Das share about the importance of collaboration in the SPARK Program at Stanford University?
    Kanad Das
    Add to my network

    Location

    San Francisco, California